Technologies

BLUE PEAK LAW GROUP

MADE FOR THE MODERN AGE

Technology Focused IP Litigation

Blue Peak Law Group is a highly specialized litigation firm with a heavy focus on technology. Our attorneys are experts in intellectual property, and have litigated innovations across a variety of industries, including semiconductor technology, consumer electronics, software, computer science, biotechnology, life sciences and beyond. Contact us today to book a consultation relating to your intellectual property protection needs and learn more about our focus in emerging tech.

Book a Consultation

The current revolution of semiconductor technology and the fast-paced innovation occurring in this field is unprecedented. Blue Peak Law Group has extensive expertise litigating and advising companies that develop and invest in semiconductor design, fabrication, and packaging technology. With a dedicated focus on this intricate and complex field, our attorneys have experience with the unique challenges of litigating semiconductor patents, including in-depth knowledge of the semiconductor foundry business and manufacturing toolsets, as well safeguarding and analyzing semiconductor source code.

Semiconductor Technology

Blue Peak Law Group has litigated dozens of consumer electronics patents, both on the plaintiff and defense side, on behalf of some of the largest and most prestigious companies in this space. Our deep understanding of emerging legal trends, including our extensive knowledge of §101 issues, allows our attorneys to develop robust legal strategies to resolve disputes quickly and efficiently.

Consumer Electronics

The attorneys of Blue Peak are highly qualified in navigating legal disputes occurring in these industries. From the development of artificial intelligence, to machine learning, cybersecurity, cloud computing, and beyond – Blue Peak is with you every step of the way when it comes to resolving the complex and high-stakes disputes within this competitive landscape. Our technical backgrounds also allow us to tackle the unique challenges of litigating cases involving software and computer science. We have experience litigating software issues under the DMCA, as well as in patent litigations in the bioinformatics, consumer electronics, and semiconductor spaces. Our experience with the intersectionality of copyright and patent law allows us to tailor our strategy to our clients’ needs.

Software & Computer Science

Recent advancements in AI and mobile hardware have resulted from improvements and optimizations to SoC, CPU, memory, GPU, and interconnect architectures. Blue Peak attorneys are experienced with the design and operation of these systems and can provide in-depth analysis of cutting-edge devices. Our expertise also allows us to provide historical context of these advances in computer architecture, such as features that were once exclusive to supercomputer and high-performance computing technology that have propagated down to mobile, hand-held, and personal computing devices today.

Computer Architecture

Now, more than ever, genetic engineering, molecular biology, diagnostics, and bioinformatics, are key in providing innovative solutions to provide personalized medicinal care. Our attorneys have experience representing companies at the forefront of this pivotal discipline, and are well-versed in the unique issues that face biotechnology companies, including § 101 eligibility issues and emerging regulatory issues. From high-stakes patent litigation to appeals processes for cutting-edge therapies, technological development and pioneering advancements in medicine and synthetic biology – we are highly qualified to conquer the disputes that arise within this critical field of work.

Biotechnology

From pharmaceuticals to medical devices, this dynamic sector drives innovations that touch every part of human life. Our attorneys are highly experienced litigating pharmaceutical and medical device cases under the Hatch-Waxman Act, and are well-versed in the regulatory intricacies of this field. Our experience has also allowed us to advise life sciences companies on the strategic acquisition of intellectual property portfolios to allow the continued development of critical therapies.